MX2017014730A - Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). - Google Patents

Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).

Info

Publication number
MX2017014730A
MX2017014730A MX2017014730A MX2017014730A MX2017014730A MX 2017014730 A MX2017014730 A MX 2017014730A MX 2017014730 A MX2017014730 A MX 2017014730A MX 2017014730 A MX2017014730 A MX 2017014730A MX 2017014730 A MX2017014730 A MX 2017014730A
Authority
MX
Mexico
Prior art keywords
proteins
gpc3
muteins
lipocalin
glypican
Prior art date
Application number
MX2017014730A
Other languages
English (en)
Spanish (es)
Inventor
Huelsmeyer Martin
Allersdorfer Andrea
Matschiner Gabriele
Hinner Marlon
Siham Bel Aiba Rachida
Aloe Michaela
Wiedenmann Alexander
Original Assignee
Pieris Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh filed Critical Pieris Pharmaceuticals Gmbh
Publication of MX2017014730A publication Critical patent/MX2017014730A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
MX2017014730A 2015-05-18 2016-05-18 Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). MX2017014730A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15167922 2015-05-18
PCT/EP2016/061058 WO2016184875A1 (en) 2015-05-18 2016-05-18 Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)

Publications (1)

Publication Number Publication Date
MX2017014730A true MX2017014730A (es) 2018-06-28

Family

ID=53180583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014730A MX2017014730A (es) 2015-05-18 2016-05-18 Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).

Country Status (13)

Country Link
US (2) US10273275B2 (enExample)
EP (1) EP3298029A1 (enExample)
JP (2) JP6942060B2 (enExample)
KR (1) KR20180008649A (enExample)
CN (2) CN107787327B (enExample)
AU (1) AU2016262838B2 (enExample)
BR (1) BR112017020961A2 (enExample)
CA (1) CA2982034A1 (enExample)
MX (1) MX2017014730A (enExample)
RU (1) RU2756318C2 (enExample)
SG (1) SG11201707872WA (enExample)
WO (1) WO2016184875A1 (enExample)
ZA (1) ZA201706605B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990798B1 (en) 2009-12-07 2019-09-25 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
AU2015261968B2 (en) 2014-05-22 2018-11-22 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
MX384075B (es) 2015-01-28 2025-03-14 Pieris Pharmaceuticals Gmbh Nuevas proteínas específicas para la angiogénesis.
ES2932425T3 (es) 2015-05-04 2023-01-19 Pieris Pharmaceuticals Gmbh Proteínas específicas para CD137
CN114316067A (zh) 2015-05-04 2022-04-12 皮里斯制药有限公司 抗癌融合多肽
BR112017020961A2 (pt) 2015-05-18 2018-07-10 Pieris Pharmaceuticals Gmbh muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação
MX390894B (es) * 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
SG10201911499TA (en) 2015-11-30 2020-01-30 Pieris Australia Pty Ltd Novel anti-angiogenic fusion polypeptides
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
CA3124441A1 (en) 2019-02-26 2020-09-03 Pieris Pharmaceuticals Gmbh Novel fusion proteins specific for cd137 and gpc3
AU2020253034A1 (en) 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
KR20230020443A (ko) 2020-06-05 2023-02-10 피어이스 파마슈티컬즈 게엠베하 4-1bb 표적화 다량체 면역조절제

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
KR100384353B1 (ko) 1994-05-18 2003-10-04 네크타르 테라퓨틱스 인터페론의건조분말제형을제조하기위한방법및조성물
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
DK1087778T3 (da) 1998-06-08 2005-12-19 Hoffmann La Roche Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US7235520B2 (en) 2000-09-21 2007-06-26 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
WO2005019254A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
ES2373055T3 (es) * 2005-08-09 2012-01-31 Oncotherapy Science, Inc. Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
US20070191272A1 (en) 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
EP1996613B1 (en) * 2006-03-20 2014-04-30 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
CA2659413C (en) 2006-08-01 2016-06-14 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
AU2008275985B2 (en) 2007-07-17 2013-09-19 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against Glypican-3
WO2009052390A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Glycosylated mammalian ngal and use thereof
EP2313430B1 (en) 2008-06-24 2018-05-02 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
EP2990798B1 (en) * 2009-12-07 2019-09-25 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
PL2580236T3 (pl) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh Muteiny lipokaliny łez wiążące IL-4 R alfa
AU2011290751B2 (en) 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
CA2817779C (en) 2010-11-15 2019-02-19 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
US20130225505A1 (en) 2011-11-23 2013-08-29 Allergan, Inc. Muteins of human tear lipcalin for treating neovascular disease of the anterior segment of the human eye
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
CA2891557A1 (en) * 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
MX384075B (es) 2015-01-28 2025-03-14 Pieris Pharmaceuticals Gmbh Nuevas proteínas específicas para la angiogénesis.
WO2016131804A1 (en) 2015-02-18 2016-08-25 Sanofi Novel proteins specific for pyoverdine and pyochelin
ES2932425T3 (es) 2015-05-04 2023-01-19 Pieris Pharmaceuticals Gmbh Proteínas específicas para CD137
BR112017020961A2 (pt) 2015-05-18 2018-07-10 Pieris Pharmaceuticals Gmbh muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação

Also Published As

Publication number Publication date
US20190309037A1 (en) 2019-10-10
ZA201706605B (en) 2020-05-27
JP7217783B2 (ja) 2023-02-03
SG11201707872WA (en) 2017-10-30
KR20180008649A (ko) 2018-01-24
JP2018519802A (ja) 2018-07-26
AU2016262838B2 (en) 2020-10-08
RU2017135605A (ru) 2019-06-18
WO2016184875A1 (en) 2016-11-24
BR112017020961A2 (pt) 2018-07-10
JP6942060B2 (ja) 2021-09-29
CN114456252A (zh) 2022-05-10
EP3298029A1 (en) 2018-03-28
JP2021184725A (ja) 2021-12-09
US10273275B2 (en) 2019-04-30
CN107787327A (zh) 2018-03-09
CN107787327B (zh) 2022-02-08
AU2016262838A1 (en) 2018-01-04
CA2982034A1 (en) 2016-11-24
RU2017135605A3 (enExample) 2019-11-13
US10787491B2 (en) 2020-09-29
US20180141988A1 (en) 2018-05-24
RU2756318C2 (ru) 2021-09-29

Similar Documents

Publication Publication Date Title
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
ZA202501799B (en) Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
EA201792047A1 (ru) Новые соединения
MX384363B (es) Nuevos polipéptidos de unión específica y usos de los mismos.
MX390894B (es) Polipéptido de fusión anti-cáncer.
WO2017081211A3 (en) Antigen-binding polypeptides directed against cd38
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
MY177065A (en) 4-1bb binding molecules
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
UY38740A (es) Mutantes de fgf21 y usos del mismo
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
PH12019500571A1 (en) Anti-pd-1 antibodies
HK1258509A1 (zh) Gitr激动剂
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
SG10201906859PA (en) Novel proteins specific for angiogenesis
PH12017500032B1 (en) Improved a㟠protofibril binding antibodies
CY1124667T1 (el) Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα
WO2014076321A8 (en) Novel specific-binding polypeptides and uses thereof
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
MX2017005467A (es) Polipéptidos de fusión de serpina y métodos para utilizar los mismos.